Efficacy and safety of intranasal medications for allergic rhinitis: Network meta‐analysis
Allergy · 2025-01 · 80 (1) · 94-105
DOI: 10.1111/all.16384 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Allergy, online erschienen am 16.11.2024. Verfasst von Bernardo Sousa-Pinto und 22 weiteren Autor:innen. Beteiligte Einrichtung: MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences; Faculty of Medicine, University of Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Administration, Intranasal, Rhinitis, Allergic, Histamine Antagonists, Adrenal Cortex Hormones. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Allergic Rhinitis and its Impact on Asthma.
Abstract (Originalsprache)
Background
Intranasal antihistamines (INAH), corticosteroids (INCS), and their fixed combinations (INAH+INCS) are one of the cornerstones of the treatment of allergic rhinitis (AR). We performed a systematic review and network‐meta‐analysis comparing the efficacy and safety of INAH, INCS, and INAH+INCS in patients with AR.
Methods
We searched four electronic bibliographic databases and three clinical trial databases for randomised controlled trials assessing the use of INAH, INCS, and INAH+INCS in adults with seasonal or perennial AR. We performed a network meta‐analysis on the Total Nasal Symptom Score, Total Ocular Symptom Score, Rhinoconjunctivitis Quality‐of‐Life Questionnaire, development of adverse events, and withdrawals due to adverse events. Certainty of evidence was assessed using GRADE‐NMA.
Results
We included 167 primary studies, most of which assessed patients with seasonal AR. Among individual medications, azelastine‐fluticasone, and fluticasone furoate were the most frequently highest‐ranked interventions for efficacy outcomes, being regularly associated with clinically meaningful larger improvements when compared to other active treatments. Considering drug classes, INAH+INCS were the highest‐ranked interventions for all outcomes in which they were assessed, followed in most cases by INCS. In 105 out of 184 comparisons in seasonal AR, and 28 out of 97 comparisons in perennial AR, certainty of evidence was considered “high” or “moderate”.
Conclusion
Intranasal medications for AR display clinically relevant differences in their efficacy, but all show a good safety profile. To our knowledge, this is the first network meta‐analysis comparing INAH, INCS, and INAH+INCS in AR, providing relevant evidence for guideline developers and practising physicians on the most efficacious treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences; Faculty of Medicine, University of Porto, Porto, Portugal.
- CINTESIS@RISE-Health Research Network, MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal.
- Clinical Epidemiology and Research Center (CERC), Humanitas University and Humanitas Research Hospital, Milan, Italy.
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
- Unit of Anatomy, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal.
- Department of Ophthalmology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
ORCID-Profile: Rafael José Vieira, Antonio Bognanni, Miguel Campos-Lopes, Nuno Lourenço-Silva, Ivan Chérrez-Ojeda, Ludger Klimek, Juan Jose Yepes Nuñez, Torsten Zuberbier, Jean Bousquet
Förderung
- Allergic Rhinitis and its Impact on Asthma
Zitieren
APA
Sousa-Pinto, B., Vieira, R. J., Bognanni, A., Gil-Mata, S., Ferreira-da-Silva, R., Ferreira, A., Cardoso-Fernandes, A., Ferreira-Cardoso, H., Marques-Cruz, M., Duarte, V. H., Castro-Teles, J., Campos-Lopes, M., Teixeira-Ferreira, A., Lourenço-Silva, N., Chérrez-Ojeda, I., Bedbrook, A., Klimek, L., Nuñez, J. J. Y., Zuberbier, T., …, & ARIA 2024 guideline panel (2025). Efficacy and safety of intranasal medications for allergic rhinitis: Network meta‐analysis. Allergy, 80(1), 94-105. https://doi.org/10.1111/all.16384
Vancouver
Sousa-Pinto B, Vieira RJ, Bognanni A, Gil-Mata S, Ferreira-da-Silva R, Ferreira A, et al. Efficacy and safety of intranasal medications for allergic rhinitis: Network meta‐analysis. Allergy. 2025;80(1):94-105. doi:10.1111/all.16384
BibTeX
@article{SousaPinto2025,
author = {Sousa-Pinto, Bernardo and Vieira, Rafael José and Bognanni, Antonio and Gil-Mata, Sara and Ferreira-da-Silva, Renato and Ferreira, André and Cardoso-Fernandes, António and Ferreira-Cardoso, Henrique and Marques-Cruz, Manuel and Duarte, Vítor Henrique and Castro-Teles, João and Campos-Lopes, Miguel and Teixeira-Ferreira, Ana and Lourenço-Silva, Nuno and Chérrez-Ojeda, Ivan and Bedbrook, Anna and Klimek, Ludger and Nuñez, Juan Jose Yepes and Zuberbier, Torsten and Fonseca, João A and Schünemann, Holger J and Bousquet, Jean and ARIA 2024 guideline panel, ARIA 2024 guideline panel},
title = {Efficacy and safety of intranasal medications for allergic rhinitis: Network meta‐analysis},
journal = {Allergy},
year = {2025},
volume = {80},
number = {1},
pages = {94--105},
doi = {10.1111/all.16384}
}
EUVIMED